Genelux Corporation

What they do

Genelux develops next-generation oncolytic viral immunotherapies, primarily using a proprietary modified vaccinia virus (Olvi-Vec) to selectively kill tumor cells and induce immune responses. The company has no approved products and no revenue from product sales. It operates a cGMP manufacturing facility in San Diego for clinical trial material.

Revenue drivers

• Olvi-Vec (olvimulogene nanivacirepvec) — Lead product candidate, currently in Phase 3 (OnPrime/GOG-3076) for platinum-resistant/refractory ovarian cancer, Phase 2 (VIRO-25) for recurrent non-small cell lung cancer, and Phase 1b/2 in China for recurrent small cell lung cancer. No commercial revenue.
• Newsoara License Agreement — Exclusive license to Newsoara for Olvi-Vec in China (including Taiwan, Hong Kong, Macau) for all human uses. Potential milestone payments and royalties, but no revenue recognized to date.

Recent performance

For the six months ended June 30, 2026, net loss was $18.4 million, compared to $14.9 million in the same period of 2025. Accumulated deficit reached $301.9 million as of June 30, 2026. Annual net losses have grown from $5.2 million in 2022 to $32.1 million in 2025, with annual revenue near zero. As of June 30, 2026, cash and equivalents were $9.2 million, with total cash, restricted cash, and marketable securities of $18.7 million.

Strategy

The company is focused on executing late-stage clinical trials to demonstrate platinum-resensitization with Olvi-Vec in multiple indications. It plans to leverage its CHOICE platform and cGMP manufacturing capability to build a fully-integrated therapeutics company. Management intends to finance operations through equity offerings, including an ATM program, and potential collaborations.

Risks

• Significant recurring losses — The company has never generated revenue from product sales and expects to incur significant and increasing losses for the foreseeable future.
• Substantial additional capital needed — The company will require substantial additional funding; failure to raise capital could delay or terminate development programs.
• Single product candidate concentration — Olvi-Vec is the only product candidate in clinical development; failure would materially harm the business.
• Novel approach uncertainty — The oncolytic immunotherapy approach is novel, making development time and cost difficult to predict and regulatory approval uncertain.

Outlook

Management expects cash and marketable securities totaling $18.7 million as of June 30, 2026 to fund operations into the first quarter of 2027. They plan to continue advancing Olvi-Vec through Phase 3 and Phase 2 trials, and will need to raise additional capital to sustain operations beyond that point. The company anticipates incurring significant and increasing expenses for clinical development, manufacturing, regulatory activities, and potential commercialization.